Unnamed: 0,RowID,Outcome,Intervention,Comparator,Answer,Reasoning,XML
1,2425,venous ulcer healing,two-layer bandage,compression stocking,no significant difference,"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).",3298351
2,2425,venous ulcer healing,four-layer bandage,compression stocking,no significant difference,"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).",3298351
3,2425,venous ulcer healing,compression therapy,no treatment,significantly increased,We compared the dynamics of ulcer healing of patients treated with different types of compression therapy. The changes of ulceration area were statistically significant regardless of the type of compression therapy.,3298351
4,2425,venous ulcer healing,four-layer bandage,two-layer bandage,no significant difference,"What is more, no statistically significant advantage of any of the applied types of compression therapy was found (Table II).",3298351
5,2425,CEAP scores,four-layer bandage,two-layer bandage,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
6,2425,CEAP scores,four-layer bandage,compression stocking,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
7,2425,CEAP scores,two-layer bandage,compression stocking,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
8,2425,venous ulcer healing,ProGuide system,Profore compression,no significant difference,"In our own research, the comparison of two pre-prepared Profore and ProGuide compression systems as well as elastic compression, that is to say, compression stockings, did not show statistically significant differences.",3298351
9,2425,faster healing dynamics,layer compression,Compression stocking,significantly increased,"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed.",3298351
10,2425,higher percentage of healed area,layer compression,Compression stocking,significantly increased,"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed.",3298351
11,2286,interval to delivery,tocolysis,antibiotic therapy and tocolysis,no significant difference,"no significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
12,2286,birth weight,tocolysis,antibiotic therapy and tocolysis,no significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
13,2286,neonatal outcomes,tocolysis,antibiotic therapy and tocolysis,no significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
14,2286,infection,antibiotic therapy,placebo,significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group.,2366143
15,2270,gestational age,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
16,2270,frequency of contractions,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
17,2270,cervical Bishop's score,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
18,2270,white blood cell count,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
19,51310,pregnancy,twice weekly single iron tablet,weekly supplements of two iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
20,51310,pregnancy,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
21,51310,pregnancy,daily single iron tablets,twice weekly single iron tablet,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
22,51310,birth outcome,twice weekly single iron tablet,weekly supplements of two iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
23,51310,birth outcome,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
24,51310,birth outcome,daily single iron tablets,twice weekly single iron tablet,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
25,51310,side effects,weekly supplements of two iron tablets,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
26,51310,side effects,daily single iron tablets,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
27,51310,side effects,twice weekly single iron tablet,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
28,51310,hemoglobin levels at week 28,weekly supplements of two iron tablets,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
29,51310,hemoglobin levels at week 28,daily single iron tablets,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
30,51310,hemoglobin levels at week 28,twice weekly single iron tablet,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
31,51310,hemoglobin levels at week 38,weekly supplements of two iron tablets,twice weekly single iron tablet,significantly decreased,"When comparing the final levels at 38 weeks, a significant difference was observed between Group B and the other two groups in this iron status indicator (P = 0.035). This difference was also of marginal clinical significance (19.9 μg/L in Group B).",3233526
32,51310,hemoglobin levels at week 38,daily single iron tablets,twice weekly single iron tablet,significantly decreased,"When comparing the final levels at 38 weeks, a significant difference was observed between Group B and the other two groups in this iron status indicator (P = 0.035). This difference was also of marginal clinical significance (19.9 μg/L in Group B).",3233526
33,51310,ferritin levels at week 28,daily single iron tablets,weekly supplements of two iron tablets,significantly increased,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
34,51310,ferritin levels at week 28,daily single iron tablets,twice weekly single iron tablet,significantly increased,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
35,51310,ferritin levels at week 38,weekly supplements of two iron tablets,twice weekly single iron tablet,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
36,51310,ferritin levels at week 38,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
37,51310,ferritin levels at week 38,daily single iron tablets,twice weekly single iron tablet,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
38,46206,symptoms of RA,golimumab and methotrexate,methotrexate,significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.,2674549
39,46206,physical function,golimumab and methotrexate,methotrexate,significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.,2674549
40,46206,ACR20 ,placebo and methotrexate,Golimumab 100 mg and placebo,no significant difference,,2674549
41,46206,Median HAQ-DI score,placebo and methotrexate,Golimumab 100 mg and placebo,no significant difference,"No difference in the improvement in median HAQ-DI score was observed between group 2 and group 1 (−0.13; p = 0.240). Overall, 38.6% of patients in group 1, 45.3% of patients in group 2 (p = 0.276), 68.2% of patients in group 3 (p<0.001) and 72.1% of patients in group 4 (p<0.001) achieved a reduction in HAQ-DI score of 0.25 or greater.",2674549
42,46206,HAQ-DI score,50mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"At week 24, patients in the combined groups 3 and 4 also showed significantly greater improvement in the median HAQ-DI score (−0.44, p<0.001) compared with group 1 (−0.13), with improvements of −0.38 (p = 0.001) in group 3 and −0.50 (p<0.001) in group 4 (table 2).",2674549
43,46206,HAQ-DI score,100mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"At week 24, patients in the combined groups 3 and 4 also showed significantly greater improvement in the median HAQ-DI score (−0.44, p<0.001) compared with group 1 (−0.13), with improvements of −0.38 (p = 0.001) in group 3 and −0.50 (p<0.001) in group 4 (table 2).",2674549
44,46206,serious adverse events,100mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
45,46206,serious adverse events,100mg of Golimumab and methotrexate,Golimumab 100 mg and placebo,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
46,46206,serious adverse events,100mg of Golimumab and methotrexate,50mg of Golimumab and methotrexate,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
47,4505,induction-delivery interval,misoprostol,dinoprostone,significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).",524504
48,4505,number of women who deliver within 12 hours,misoprostol,dinoprostone,significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05)",524504
49,4505,number of women who deliver within 24 hours,misoprostol,dinoprostone,significantly increased,,524504
50,4505,spontaneous rupture of membranes,misoprostol,dinoprostone,significantly increased,"spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05)",524504
51,4505,administration of oxytocin augmentation,misoprostol,dinoprostone,significantly decreased,"there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05)",524504
52,4505,Caesarean section rate,dinoprostone,misoprostol,no significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).",524504
53,4505,abnormal fetal heart rate,dinoprostone,misoprostol,no significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).",524504
54,4505,uterine tachysystole,misoprostol,dinoprostone,significantly increased,"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05)",524504
55,4505,Uterine Hyperstimulation,misoprostol,dinoprostone,no significant difference,Uterine Hyperstimulation 2 (2.5%) 1 (1.2%) NS,524504
56,4505,Meconium stained AF,dinoprostone,misoprostol,no significant difference,Meconium stained AF 15 (18.8%) 7 (9.6%) NS,524504
57,4505,perinatal death,dinoprostone,misoprostol,no significant difference,Perinatal death 0 1(1.2%) NS,524504
58,4505,Neonatal resuscitation,dinoprostone,misoprostol,no significant difference,Neonatal resuscitation 9 (11.3%) 9 (10.8%) NS,524504
59,4505,Core blood pH,dinoprostone,misoprostol,no significant difference,Cord blood pH (arterial)1 7.28 ± 0.05 7.27 ± 0.05 NS,524504
60,4505,Hyperbilirubinemia,dinoprostone,misoprostol,no significant difference,Hyperbilirubinemia 2 9 (11.3%) 5 (6.0%) NS,524504
61,4505,Birth trauma,dinoprostone,misoprostol,no significant difference,Birth trauma 3 0 2 (2.5%) NS,524504
62,2680,rates of vacuum-assisted delivery rate,Meperidine analgesia,epidural analgesia,no significant difference,There was no statistical difference in rates of vacuum-assisted delivery rate.,1764008
63,2680,c-section,Meperidine analgesia,epidural analgesia,no significant difference,"Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.",1764008
64,2680,duration of labor stages,Meperidine analgesia,epidural analgesia,no significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant.,1764008
65,2680,oxytocin augmentation,Meperidine analgesia,epidural analgesia,no significant difference,"Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation",1764008
66,2680,preanalgesic visual analog pain,Meperidine analgesia,epidural analgesia,no significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 ± 1.2 vs. intravenous meperidine, 9 ± 1.3; P = 0.09)",1764008
67,2680,pain levels during first stage labor,epidural analgesia,Meperidine analgesia,significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor",1764008
68,2680,pain levels during second stage labor,epidural analgesia,Meperidine analgesia,significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor",1764008
69,2680,hypotension,epidural analgesia,Meperidine analgesia,significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001),1764008
70,2680,nausea and vomiting,Meperidine analgesia,epidural analgesia,no significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%),1764008
71,2680,obstetric outcome,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
72,2680,obstetric intervention,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
73,2680,neonatal outcome,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
74,35535,continuous abstienence at week 12,varenicline,placebo,significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001)",3281242
75,35535,continuous abstienence at 24 week follow up,varenicline,placebo,significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001)",3281242
76,35535,frequency of quit events by day 35,varenicline,placebo,no significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062). ",3281242
77,35535,time to make first quit attempt,varenicline,placebo,significantly decreased,"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).",3281242
78,36775,improved A1C,detemir,glargine,no significant difference,Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149),2875419
79,36775,number of patients with A1C <7%,detemir,glargine,no significant difference,with similar proportions of patients achieving A1C <7% (P = 0.254),2875419
80,36775,number of patients with A1C <6.5%,detemir,glargine,significantly increased,more detemir-treated patients reaching A1C <6.5% (P = 0.017),2875419
81,36775,Hypoglycemia,detemir,glargine,no significant difference,Hypoglycemia risk was similar.,2875419
82,36775,Weight Gain,glargine,detemir,significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).",2875419
83,36775,frequency of insulin doses,glargine,detemir,significantly decreased,"Insulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day (P < 0.001) (Fig. 1B)",2875419
84,36775,drop-out rate,detemir,glargine,significantly decreased,"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.",2875419
85,43880,IVD comlication rates,routine replacement,staff inclination replacement,no significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).",2944158
86,43880,time until first complication,routine replacement,staff inclination replacement,no significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).",2944158
87,43880,infections,routine replacement,staff inclination replacement,no significant difference,There were no local infections or IVD-related bloodstream infections in either group. ,2944158
88,43880,therapy duration,routine replacement,staff inclination replacement,no significant difference,IV therapy duration did not differ between groups (P = 0.22),2944158
89,43880,frequency of replacements,routine replacement,staff inclination replacement,significantly increased,"but more (P = 0.004) IVDs were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5)",2944158
90,43880,cost per patient,routine replacement,staff inclination replacement,significantly increased,with significantly higher hospital costs per patient (P < 0.001).,2944158
91,43880,IVD complications per person,routine replacement,staff inclination replacement,no significant difference,,2944158
92,43880,phlebitis,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
93,43880,infiltration,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
94,43880,occlusion,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
95,43880,IVD dwell times,staff inclination replacement,routine replacement,significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).",2944158
96,24976,frequency of healed index ucler after 1 year,HBOT ,placebo,significantly increased,complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03),2858204
97,24976,hypoglycemia occuring after treatment,HBOT ,placebo,no significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).",2858204
98,24976,downsizing of ucler area 2 weeks after treatment,HBOT ,placebo,significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037)",2858204
99,2871176,HbA1c level at 26 weeks,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%)",2871176
100,2871176,HbA1c level at 26 weeks,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P &lt; 0.0001, baseline 8.4%) when added to glimepiride.",2871176
101,2871176,Fasting plasma glucose at week 26,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l)",2871176
102,2871176,Fasting plasma glucose at week 26,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).",2871176
103,2871176,Postprandial plasma glucose,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l)",2871176
104,2871176,Postprandial plasma glucose,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P &lt; 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.,2871176
105,2871176,HbA1c level at 26 weeks,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P &lt; 0.0001, baseline 8.4%) when added to glimepiride.",2871176
106,2871176,HbA1c level at 26 weeks,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,All liraglutide doses were superior to placebo (P &lt; 0.0001),2871176
107,2871176,HbA1c level at 26 weeks,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P &lt; 0.0001, baseline 8.4%) when added to glimepiride.",2871176
108,2871176,HbA1c level at 26 weeks,Liraglutide (0.6 mg) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,Liraglutide 0.6 mg was non-inferior to rosiglitazone,2871176
109,2871176,HbA1c level at 26 weeks,Rosiglitazone plus glimepiride,Placebo plus glimepiride,Significantly decreased,Rosiglitazone also was superior to placebo (P &lt; 0.0001),2871176
110,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001),2871176
111,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001),2871176
112,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003),2871176
113,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003),2871176
114,2871176,Patients reaching HbA1c goals less than 7.0% ,Liraglutide (1.8 mg) plus glimepiride,Liraglutide (1.2 mg) plus glimepiride,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).",2871176
115,2871176,Fasting plasma glucose at week 26,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l)",2871176
116,2871176,Fasting plasma glucose at week 26,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001)",2871176
117,2871176,Fasting plasma glucose at week 26,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).",2871176
118,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%).,2871176
119,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%).,2871176
120,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%).,2871176
121,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).",2871176
122,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).",2871176
123,2871176,Postprandial plasma glucose,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l)",2871176
124,2871176,Postprandial plasma glucose,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P &lt; 0.0001),2871176
125,2871176,Postprandial plasma glucose,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P &lt; 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.,2871176
126,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone",2871176
127,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone",2871176
128,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone",2871176
129,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,"The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.",2871176
130,2871176,Weight gain,Rosiglitazone plus glimepiride,Liraglutide plus glimepiride,Significantly increased,"Unlike rosiglitazone, weight did not increase substantially with liraglutide and the differences between rosiglitazone and liraglutide were statistically significant (−2.3 to −1.4 kg; P &lt; 0.0001)",2871176
131,2871176,Proinsulin : insulin ratio,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
132,2871176,Proinsulin : insulin ratio,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
133,2871176,Proinsulin : insulin ratio,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
134,2871176,Proinsulin : insulin ratio,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
135,2871176,HOMA-B,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly increased,HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05),2871176
136,2871176,HOMA-B,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly increased,HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05),2871176
137,2871176,HOMA-B,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)",2871176
138,2871176,HOMA-B,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)",2871176
139,2871176,HOMA-IR,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,There were no significant differences between treatments for HOMA-IR.,2871176
140,2871176,HOMA-IR,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,There were no significant differences between treatments for HOMA-IR.,2871176
141,2871176,Reductions in systolic blood pressure,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)",2871176
142,2871176,Reductions in systolic blood pressure,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)",2871176
143,2871176,Reductions in systolic blood pressure,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).",2871176
144,2871176,Reductions in systolic blood pressure,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).",2871176
145,2871176,Decreases in diastolic blood pressure,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.",2871176
146,2871176,Decreases in diastolic blood pressure,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.",2871176
147,2871176,Pulse variations,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).,2871176
148,2871176,Pulse variations,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).,2871176
149,2871176,Pulse variations,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).,2871176
150,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
151,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
152,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
153,2871176,Changes in calcitonin at week 26,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.,2871176
154,2871176,Changes in calcitonin at week 26,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.,2871176
155,2708184,Self-selected overground walk velocity,Body-weight supported treadmill training combined with Lokomat,Manually-assisted body-weight supported treadmill training,No significant difference,No significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of training.,2708184
156,2708184,Paretic step length ratio,Body-weight supported treadmill training combined with Lokomat,Manually-assisted body-weight supported treadmill training,No significant difference,No significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of training.,2708184
157,2708184,Locomotor-training effects,Fast treadmill speed,Slow treadmill speed,No significant difference,"Our second aim was to assess locomotor-training effects at faster vs. slower treadmill speeds. As anticipated, independent of whether training occurred in the Lokomat or manual-BWSTT mode, average weekly training speeds within the fast and slow groups were similar, p ≥ 0.29",2708184
158,2708184,Self-selected overground walk velocity,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Although an equal number of participants (n = 7) produced a training related increase in self-selected overground walking speed in each group, a significant difference, p = 0.04, was revealed only in the Lokomat group with a pre-post intervention difference of 0.10 m/s and an effect size of 0.32",2708184
159,2708184,6-minute walk test,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),No significant difference,"With the exception of the 6-minute walk test and LLFDI, p ≥ 0.16, all secondary measures revealed significant improvements within the Lokomat group",2708184
160,2708184,Late Life Function and Disability Instrument,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),No significant difference,"With the exception of the 6-minute walk test and LLFDI, p ≥ 0.16, all secondary measures revealed significant improvements within the Lokomat group",2708184
161,2708184,Improvement in lower extremity Fugl-Meyer score ,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Fast overground walk speed improved from pre- to post-training in 6 of 8 Lokomat participants, p = 0.05, with a small effect size of 0.15 (Figure 2A). Lower extremity Fugl-Meyer score improvements were also noted, p = 0.04, with an effect size of 0.60 and higher scores in 5 of 8 Lokomat group participants",2708184
162,2708184,Physical performance battery scores,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Similarly, short physical performance battery scores were improved in the Lokomat group, p = 0.04, with an effect size of 0.29 and improvements in 5 of 8 participants.",2708184
163,2708184,Berg Balance Scale score,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved)",2708184
164,2708184,Berg Balance Scale score,Manually-assisted body-weight supported treadmill training (post-test),Manually-assisted body-weight supported treadmill training (pre-test),Significantly increased,"Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved), and manual group, p = 0.02, effect size 0.57 (7 participants improved)",2708184
165,3001156,Care-seeking from qualified providers for ill newborns  ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly increased,there was a highly significant (p&lt;0.00001) increase in the proportion of families that sought care from qualified providers for sick newborns in the intervention arm (Fig. 2 and Rows 5 and 7 of Table 2) and a non-significant increase in the comparison arm (Rows 5 and 8).,3001156
166,3001156,Care-seeking from the Kumudini Hospital for ill newborns ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly increased,"care-seeking for sick newborns specifically from the Kumudini Hospital increased significantly in both intervention and comparison arms, but the increase was of a much greater magnitude in the intervention arm",3001156
167,3001156,Care-seeking from unqualified providers (such as village doctors) for ill newborns  ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly decreased,"the proportion of families who sought care from unqualified providers, such as unlicensed village doctors, remained unchanged in the comparison arm, but declined significantly in the intervention arm",3001156
168,2864284,Parasite clearance at day 1,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"Initial parasitological responses were faster with dihydroartemisinin-piperaquine (Figure 4); in the dihydroartemisinin-piperaquine group 241/264 (91.3%) of patients cleared their parasitaemia at day 1 compared to 209/265 (78.9%) in the chloroquine group (p &lt; 0.001, relative risk of clearance in chloroquine group = 0.87, 95% CI 0.81-0.93).",2864284
169,2864284,Parasite clearance at day 2,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59).",2864284
170,2864284,Recurrent infections at day 56,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"By the end of the 56-day follow-up period, there were 23 recurrences (parasitological failures) in the chloroquine group and 7 in the dihydroartemisinin-piperaquine group, giving a day 56 failure rate of 8.9% (95% CI 6.0 - 13.1%) in the chloroquine group and 2.8% (1.4 - 5.8%) in the dihydroartemisinin-piperaquine group (Figure 2).",2864284
171,2864284,Superiority of treatment given by survival curves,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,The log-rank test comparing the survival curves confirmed the superiority of dihydroartemisinin-piperaquine over chloroquine (p = 0.003).,2864284
172,2864284,Serious adverse events,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,Both regimens were well tolerated and no serious adverse events were reported.,2864284
173,2864284,Baseline white blood cell count,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"Patient characteristics at baseline were broadly similar between the two treatment groups (Table 1) except that the median white blood cell count was lower in the chloroquine group compared with dihydroartemisinin-piperaquine (median 6.0 vs. 6.6 × 109/l respectively, p = 0.02).",2864284
174,2864284,Fever resolution by day 1,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"In terms of resolution of fever (defined as axillary temperature &gt;37.0°C) dihydroartemisinin-piperaquine was again superior (Figure 4), with 29/266 (10.9%) of the dihydroartemisinin-piperaquine group febrile on day 1 compared to 45/268 (16.8%) in the chloroquine group (p = 0.049).",2864284
175,2864284,Fever resolution by day 2,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"By day 2 there was no longer a significant difference in the proportion with fever (3/265 (1.1%) for dihydroartemisinin-piperaquine, 9/264 (3.4%) for chloroquine, p = 0.08).",2864284
176,2864284,Headache,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"At day 1, headache was less frequent in the dihydroartemisinin-piperaquine arm (105/265 (39.6%)) compared to the chloroquine arm (145/266 (54.5%), p = 0.001)",2864284
177,2864284,Cure rate at day 28,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,The day 28 cure rate was 100% in both arms,2864284
178,2864284,Parasitaemias associated with gametocytaemia,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"Twenty-one of 30 (70%) recurrent parasitaemias were associated with gametocytaemia, with no significant difference between treatment arms in terms of proportion of recurrent patients with gametocytaemia (16/23 and 5/7 for chloroquine and dihydroartemisinin-piperaquine respectively, p = 1.0).",2864284
179,2864284,Pruritus,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"There was a significant increase in the proportion of patients with pruritus in the chloroquine arm compared to dihydroartemisinin-piperaquine on days 1, 2 and 3; on day 1, 15/268 subjects in the chloroquine arm had pruritus compared to 2/266 in the dihydroartemisinin-piperaquine arm (p = 0.002, relative risk 7.44, 95% CI 1.71-32.3), consistent with the known side-effects of chloroquine.",2864284
180,2864284,Haemoglobin concentration,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,There were no significant differences between the two arms in haemoglobin concentration or occurrence of anaemia (haemoglobin &lt; 10 g/dl) at any stage during follow-up (all p &gt; 0.5).,2864284
181,2517154,Severity of pain,Infliximab,Placebo,No significant difference,Pain severity decreased during the treatment by 30% in both the placebo (P &lt; 0.001) and infliximab groups (P &lt; 0.001).,2517154
182,2517154,Nodules diameters,Infliximab,Placebo,No significant difference,"No effect of treatment was found upon the mean diameters of the nodules as measured by TVU. For the placebo group (n = 7) and the infliximab group (n = 13), the diameters were 15.2 ± 4.6 and 13.6 ± 3.2 mm, during Visit 3, 15.1 ± 5.12 and 14.25 ± 3.5 mm, during Visit 5, 13.5 ± 4.9 and 15.6 ± 3.5 mm and during Visit 6, 13.2 + 3.4 and 15.1 + 2.38 mm.",2517154
183,2517154,Endometrial thickness,Infliximab,Placebo,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3–18) and 7.8 (1.9–11) mm and for the placebo group 7.7 (1.8–23) and 8.2 (3–15) mm, respectively.",2517154
184,2517154,Extend of the disease as visualized during surgery,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.",2517154
185,2517154,Macroscopic aspect of the tissue,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.",2517154
186,2517154,Surgery duration,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates",2517154
187,2517154,Bleeding during surgery,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates",2517154
188,2517154,Tissue examination by routine pathology,Infliximab,Placebo,No significant difference,Routine pathology (FC) also showed no obvious differences between the two groups.,2517154
189,2517154,Pain estimates after surgery,Infliximab,Placebo,No significant difference,"After surgery, all pain estimates decreased to less than 10% of the baseline in both groups (Figs&nbsp;1 and 2), and no differences were found between the placebo and the infliximab group (two-way analysis of variance).",2517154
190,2517154,Pain killers intake,Infliximab,Placebo,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P &lt; 0.01)",2517154
191,2517154,Dysmenorrhea scores,Infliximab,Placebo,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P &lt; 0.01), and higher dysmenorrhea scores (P &lt; 0.001 for physician assessment, for patient VAS scales and for patient diary).",2517154
192,1852268,obstetric/postpartum infection or gynecologic/postoperative infection,"Inravenous ertapenem, 1 g once a day","Intravenous piperacillin–tazobactam, 3.375 g every 6 hours",No significant difference,"At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.",1852268
193,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit &amp; Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
194,3187863,Labour dystocia,Midwife-led unit,Normal unit &amp; Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
195,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit &amp; Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
196,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit &amp; Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
197,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit &amp; Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
198,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit &amp; Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
199,3187863,"Neonatal outcomes were evaluated by Apgar score &lt;7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit &amp; Special unit,No significant difference,"An Apgar score &lt;7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
200,2688140,The survival rate / overall mortality of patients with ARDS,Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).",2688140
201,2688140,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS",Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2).",2688140
202,4106715,Prolonged abstinence from smoking rates to 6 months,high Ab group,placebo,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71)",4106715
203,4106715,Prolonged abstinence from smoking rates to 6 months,low Ab group,placebo,No significant difference,"ith no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).",4106715
204,4106715,Prolonged abstinence from smoking rates to 12 months,high Ab group,placebo,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).",4106715
205,4106715,Prolonged abstinence from smoking rates to 12 months,low Ab group,placebo,No significant difference,Prolonged abstinence from smoking rates to 6 months	low Ab group	placebo	No significant difference	ith no significant differences between the placebo,4106715
206,4106715,Reduction of daily cigarette consumption and cotinine,non-abstainers (weeks 19–52) with high Ab levels,non-abstainers in the placebo group,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C",4106715
207,4106715,attain 8 weeks continuous abstinence from weeks 19 through 26,recipients with the highest serum anti-nicotine antibody response (top 30% by AUC),placebo group,Significantly increased,"3’AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).",4106715
208,2206488,"Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I",dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,"procalcitonin (0.2 versus 1.4, p &lt; 0.001), IL 8 (5.6 versus 94.8, p &lt; 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.",2206488
209,2206488,Cardiac index ,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly increased,Higher figures of the cardiac index (p = 0.010),2206488
210,2206488,systemic vascular resistance,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,with reduced systemic vascular resistance (p = 0.005) were noted in group A.,2206488
211,2206488,C-reactive protein (mg/l),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,C-reactive protein (mg/l) Group A	3.7 (1.0–22.6)				79.9 (50.0–131.7)	112.0 (61.1–177.6)	&lt;0.001† Group B	2.6 (0.6–10.5)				87.6 (52.4–143.0)	131.0 (71.0–228.0)	&lt;0.001†	p = 0.068*				p = 0.092*	p = 0.168*,2206488
212,2206488,IL-6 (pg/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6 (pg/ml)							 Group A	1.6 (0.4–21.8)		95.0 (13.6–405.1)	46.3 (16.1–149.5)			&lt;0.001† Group B	2.0 (0.4–60.6)		130.5 (21.7–353.8)	49.2 (14.8–214.5)			&lt;0.001†	p = 0.107*		p = 0.829*	p = 0.482*,2206488
213,2206488,IL-6r (ng/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6r (ng/ml)							 Group A	43.6 (1.7–125.0)		47.4 (0.7–109.5)	56.2 (25.2–226.3)			0.949† Group B	40.7 (15.6–94.6)		42.4 (22.2–100.5)	50.2 (13.2–104.9)			0.861†	p = 0.607*		p = 0.914*	p = 0.304*,2206488
214,1475568,Hospitalization or death,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"61% of patients in the control group had at least one hospitalization or died, and 42% of patients in the intervention group had at least 1 hospitalization or died (p = 0.13).",1475568
215,1475568,Daily weight monitoring at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"At 12 months, more patients in the intervention group reported monitoring weights daily (79% vs. 29%, p < 0.0001).",1475568
216,1475568,Heart failure-related quality of life at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"In unadjusted analysis, the control group, on average, improved 5 points on the MLHF and the intervention group improved by 1 point. The difference was not statistically significant (3.5 points, 95% CI 11, -4, p = 0.36). After adjusting for baseline differences between the groups, the difference was 2 points (95% CI 9, -5, p = 0.59) suggesting no effect on heart failure-related quality of life.",1475568
217,1475568,Baseline hypertension,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
218,1475568,Baseline diabetes,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
219,1475568,Baseline systolic dysfunction,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
220,1475568,Baseline beta-blockers intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
221,1475568,Baseline angiotensin-converting enzyme (ACE) inhibitors intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
222,1475568,Baseline digoxin intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
223,1475568,Baseline angiotensin II receptor blockers (ARBs) intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
224,1475568,Minnesota living with heart failure (MLHF) questionnaire baseline scores,Follow-up and thorough education on self-care,Standard information about self-care,Significantly decreased,The control group did have statistically significantly higher baseline MLHF scores representing worse symptoms at baseline.,1475568
225,1475568,Cardiac-related hospitalization,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"39% of patients in the control group and 34% of patients in the intervention group had at least one hospitalization for cardiac causes (p = 0.55). The unadjusted IRR was 0.79 (95% CI 0.42, 1.5). After adjusting for baseline differences, the IRR was 0.85 (95% CI 0.44, 1.7).",1475568
226,1475568,Knowledge about heart failure,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"Heart failure related knowledge improved more in the intervention group than in the control group. Mean difference in score improvement was 12 percentage points (95% CI 6, 18; p < 0.001).",1475568
227,1475568,Self-efficacy,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"Heart failure self-efficacy improved more in the intervention group than in the control group. Mean difference in score improvement was 2 points (95% CI 0.7, 3.1; p = 0.0026).",1475568
228,1475568,Baseline life-quality score,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"Twenty-four patients in each group had inadequate literacy based on the S-TOFHLA (Table 2). Among these patients, there was no difference in quality of life score in unadjusted and adjusted analyses (difference = -1.6; 95% CI -15, 12); p = 0.81). For the combined outcome of hospitalization or death, the unadjusted IRR was 0.77 (95% CI 0.30, 1.94). After adjusting for baseline differences, the IRR was 0.39 (95% CI 0.16, 0.91).Seventy-five patients had marginal or adequate literacy based on the S-TOFHLA. We found no difference in quality of life score in unadjusted and adjusted analyses (difference = -4.2; 95% CI -14, 6; p = 0.40). Among patients in the higher literacy group, the unadjusted IRR for hospitalization or death was 0.65 (95% CI 0.33, 1.3). After adjusting for baseline differences, the IRR was 0.56 (95% CI 0.30, 1.04). We did not find a statistically significant effect modification between literacy and the intervention.",1475568
229,3090298,Uncorrected distance visual acuity at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
230,3090298,Uncorrected distance visual acuity at 3 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
231,3090298,Uncorrected distance visual acuity at 1 month,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),Significantly decreased,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
232,3090298,Corrected distance visual acuity at 1 month,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),Significantly decreased,"CDVA was statistically different between groups at 1 month, with 24% of the PRK group losing a line or more from preoperative values, while 9% of eyes in the thin-flap LASIK group lost only 1 line at 1 month. No eyes in the thin-flap LASIK group lost more than 1 line. Also, 39% of eyes in the thin-flap group gained a line by 1 month compared with only 12% of eyes in the PRK group.",3090298
233,3090298,Corrected distance visual acuity at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,Significant differences were not found between treatment groups in contrast sensitivity (P ≥ 0.156) or CDVA (P = 0.800) at postoperative 6 months.,3090298
234,3090298,1 line or more of CDVA at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"At 6 months 64% and 56% of eyes had gained a line or more of CDVA in the PRK and thin-flap LASIK groups, respectively (P = 0.462).",3090298
235,3090298,Contrast sensitivity,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Contrast sensitivity measurements at 3, 6, 12, and 18 cycles per degree (cpd) in each group are shown in Figure 1. There were no differences between groups at any cpd at any time in the study (P ≥ 0.156).",3090298
236,3090298,Contrast sensitivity,Thin-flap laser in situ keratomileusis (LASIK) ,Pre-surgery baseline,No significant difference,The thin-flap LASIK group showed no change in contrast sensitivity postoperatively (P > 0.131),3090298
237,3090298,Contrast sensitivity at 1 month seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively.",3090298
238,3090298,Contrast sensitivity at 3 months seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,No significant difference,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).",3090298
239,3090298,Contrast sensitivity at 1 month seen at 12 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively.",3090298
240,3090298,Contrast sensitivity at 6 months seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).",3090298
241,3090298,Higher-order aberrations during the study,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"There were no significant differences between groups in any HOAs throughout the study (P ≥ 0.101), with all P values at 6 months ≥0.63.",3090298
242,3090298,Higher-order aberrations at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"There were no significant differences between groups in any HOAs throughout the study (P ≥ 0.101), with all P values at 6 months ≥0.63.",3090298
243,2922723,Sputum expectoration during a single session,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,"Significantly more sputum was expectorated during a single treatment session and over a 24 h period (mean difference 4.4 g and 6.9 g, respectively) with usual ACTs than with HFCWO (p<0.001).",2922723
244,2922723,FEV1%,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant change in FEV1% or oxygen saturation was observed after either HFCWO or usual ACTs compared with baseline.,2922723
245,2922723,O2 saturation,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant change in FEV1% or oxygen saturation was observed after either HFCWO or usual ACTs compared with baseline.,2922723
246,2922723,Sputum expectoration over a 24-hour period,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,"Significantly more sputum was expectorated during a single treatment session and over a 24 h period (mean difference 4.4 g and 6.9 g, respectively) with usual ACTs than with HFCWO (p<0.001).",2922723
247,2922723,Sputum expectoration between treatments in a 24-hour period,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant difference was observed in the amount of sputum expectorated when using HFCWO or usual ACT between treatments in a 24 h period.,2922723
248,2922723,Visual analogue scale scores for comfort,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No significant differences were observed in VAS scores for comfort or urinary leakage between HFCWO and usual ACT.,2922723
249,2922723,Visual analogue scale scores for urinary leakage,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No significant differences were observed in VAS scores for comfort or urinary leakage between HFCWO and usual ACT.,2922723
250,2922723,Visual analogue scale scores for efficacy,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,Patients scored the efficacy of their usual ACT significantly higher than for HFCWO (mean difference 14 mm; p=0.002).,2922723
251,2922723,Adverse events,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,Neither HFCWO nor any of the usual ACTs were associated with any adverse clinical events,2922723
252,1831737,HIV-1 incidence,Communities that received additional education and preventive measures,Communities that received standard Government services,No significant difference,"Integrated peer education, condom distribution, and syndromic STI management did not reduce population-level HIV-1 incidence in a declining epidemic, despite reducing HIV-1 incidence in the immediate male target group.",1831737
253,1831737,HIV-1 prevalence,Communities that received additional education and preventive measures,Communities that received standard Government services,Significantly increased,"HIV-1 prevalence was higher in the intervention communities than in the control communities (24% versus 21%, risk ratio 1.13 [95% CI 1.05–1.22], p = 0.001)",1831737
254,1831737,Patients infected with T. vaginalis,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
255,1831737,Secondary school education,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
256,1831737,Spatial mobility,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
257,1831737,Genital discharge history,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
258,1831737,Intake of STI treatment,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
259,1831737,Self-reported STI symptoms,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,self-reported STI symptoms were similar in both sets of communities,1831737
260,1831737,HIV/AIDS meeting attendance,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,Significantly increased,"More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33–1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52–5.17], p < 0.001)",1831737
261,1831737,Programme meeting attendance,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,Significantly increased,"More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33–1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52–5.17], p < 0.001)",1831737
262,1831737,High-risk sexual behaviour,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities.,1831737
263,2691927,Surgery duration,Laparoscopic surgery,Conventional open approach,Significantly increased,Operating time in the laparoscopy group was significantly longer than in the open group (75 min versus 50 min).,2691927
264,2691927,Visual analog scale pain score at day 1,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
265,2691927,Visual analog scale pain score at day 3,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
266,2691927,Visual analog scale pain score at day 7,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
267,2691927,Postoperative complications,Laparoscopic surgery,Conventional open approach,No significant difference,Complications were equally distributed.,2691927
268,2691927,Need for opiates,Laparoscopic surgery,Conventional open approach,Significantly decreased,Differences regarding postoperative dosage of opiates and the visual analog scale (VAS) for pain scoring system were in favor of the laparoscopic procedure.,2691927
269,2691927,Hospital permanence,Laparoscopic surgery,Conventional open approach,No significant difference,Hospital stay was also comparable: 6.5 days in the laparoscopic group versus 8.0 days in the open group (P = 0.235).,2691927
270,2691927,Ulcer mean diameter,Laparoscopic surgery,Conventional open approach,No significant difference,"The discovered ulcer perforations were found to have a mean diameter of 10 mm, which did not differ between groups",2691927
271,2691927,Ulcer location ,Laparoscopic surgery,Conventional open approach,No significant difference,Location of the perforated ulcers was distributed equally between groups,2691927
272,2691927,Median loss of blood,Laparoscopic surgery,Conventional open approach,No significant difference,Median blood loss did not differ between groups.,2691927
273,2691927,Time to nasogastric decompression,Laparoscopic surgery,Conventional open approach,No significant difference,Nasogastric decompression could be stopped after 2–3 days in both groups,2691927
274,2691927,Better scar appearance score as measured by visual analog scale,Laparoscopic surgery,Conventional open approach,Significantly increased,"The VAS score for appearance of the scar left by the respective procedures (subjectively recorded in the same way as pain) differed by 2.3 points, favoring the laparoscopic procedure (7.7 vs. 5.4; P = 0.033)",2691927
275,2375236,Prognosis enquiry,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls,2375236
276,2375236,Prognosis information given,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients.,2375236
277,2375236,Consult duration,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
278,2375236,Anxiety,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
279,2375236,Information recall,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
280,2361806,Clinical response rates at 14 weeks,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"The objective clinical response rates after 14 weeks treatment (primary end point) were 30% for ILF and 17% for ELF (risk ratio (RR) 0.57, 95% confidence interval (CI) 0.29–1.13, P=0.0766).",2361806
281,2361806,Overall response rates,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),Significantly increased,"Overall response rates over the entire treatment period for ILF and ELF were 43 and 24%, respectively (RR 0.56, 95% CI 0.33–0.97; P=0.0467).",2361806
282,2361806,Time to treatment failure,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542)",2361806
283,2361806,Overall survival,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).",2361806
284,2361806,Progression-free survival,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"Compared with ELF, the ILF regimen extended median progression-free survival, median time to treatment failure and median overall survival (Table 4). However, when the treatment groups were compared by log-rank test, there was no significant difference between the two treatments for any of these parameters",2361806
285,2361806,Grade 3/4 digestive system toxic events,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),Significantly increased,"There were more grade 3/4 gastrointestinal toxic events with ILF, notably diarrhoea, which was reported by 18% of patients compared with no reports with ELF.",2361806
286,1871574,Quit attempt of 1 week or longer reported at 3 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"With regards to quit attempts, at 3 months, there was a statistically significantly higher proportion of participants who reported a sustained quit attempt of one week or longer in the intervention group (16/43; 37%) compared to the control group (8/44; 18%) (p-value = 0.043, 95% CI (I-C) = (1, 37)%).",1871574
287,1871574,Gender,Smoking cessation advice and NRT offered,Usual care,No significant difference,"With respect to the baseline characteristics (Table 1), there was no significant difference between intervention and control groups with respect to gender or socio-economic status as measured by DEPCAT.",1871574
288,1871574,Socio-economic position,Smoking cessation advice and NRT offered,Usual care,No significant difference,"With respect to the baseline characteristics (Table 1), there was no significant difference between intervention and control groups with respect to gender or socio-economic status as measured by DEPCAT.",1871574
289,1871574,Baseline smoking habits,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
290,1871574,Baseline nicotine dependence variables,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
291,1871574,Baseline quit motivation,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
292,1871574,Baseline cotinine level,Smoking cessation advice and NRT offered,Usual care,No significant difference,There was no significant difference between the mean baseline biochemical values in the two groups,1871574
293,1871574,Baseline CO level,Smoking cessation advice and NRT offered,Usual care,No significant difference,There was no significant difference between the mean baseline biochemical values in the two groups,1871574
294,1871574,Smoking cessation at 3 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"the 9 intervention and 5 control participants determined as having quit smoking, represented quit rates of 15.3% and 8.8% respectively. However, the difference between intervention and control groups, in terms of the proportion of participants classified as quitters, did not reach statistical significance (p = 0.449, 95% CI (I-C) = (-8.4, 25.6)%).",1871574
295,1871574,Smoking reduction at 3 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"There was also a statistically significantly higher proportion of participants who reported reducing their smoking behaviour in the intervention group (35/43; 81%) compared to the control group (20/44; 45%) (p-value < 0.001, 95% CI (I-C) = (17, 55)%).",1871574
296,1871574,"Inhaling less smoke, measured at 3 months",Smoking cessation advice and NRT offered,Usual care,No significant difference,"With regards to other self-reported potential changes, such as inhaling less, or smoking less of a cigarette, there was no statistically significant difference between the groups at this timepoint.",1871574
297,1871574,"Smoking less of a cigarette, measured at 3 months",Smoking cessation advice and NRT offered,Usual care,No significant difference,"With regards to other self-reported potential changes, such as inhaling less, or smoking less of a cigarette, there was no statistically significant difference between the groups at this timepoint.",1871574
298,1871574,Smoking cessation at 6 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"there was no statistically significant difference between the intervention and control groups in terms of the proportion of participants classified as having quit (p-value = 0.530, 95% CI (I-C) =(-8.5, 23.6)%). With regards to repeated point prevalence, there were 5/59 (8.5%) in the intervention group, compared to 3/57 (5.3%) in the control group (p-value = 0.671, 95% CI (I-C) =(-9.9, 21.8)%).",1871574
299,1871574,Quit attempt of 1 week or longer reported at 6 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"At 6 months, with regards to quit attempts, a greater proportion in the intervention group reported a quit attempt of 1 week or more (14/30; 47%), compared to the control group (5/32; 16%). This result was of statistical significance (p-value = 0.018, 95% CI (I-C) = (6, 56)%).",1871574
300,1871574,Smoking habits at 6 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There were no statistically significant differences between the groups, at 6 months, in terms of any other changes in smoking behaviour.",1871574
301,2817867,Duration of surgery,Radiofrequency ablation,Hepatic resection,Significantly decreased,The operative time was significantly longer for the resection group compared to the RFA group (median of 269 minutes (range 118 to 452) versus 204 minutes (range 113 to 316); P < .0005).,2817867
302,2817867,Blood loss during surgery,Radiofrequency ablation,Hepatic resection,Significantly decreased,Operative blood loss (median 1400 mL (range 100 to 9000) versus 150 mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA.,2817867
303,2817867,Transfusion requirements,Radiofrequency ablation,Hepatic resection,Significantly decreased,Operative blood loss (median 1400 mL (range 100 to 9000) versus 150 mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA.,2817867
304,2817867,Need for ICU ,Radiofrequency ablation,Hepatic resection,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.",2817867
305,2817867,Hospital stay,Radiofrequency ablation,Hepatic resection,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.",2817867
306,2817867,Rate of complications,Radiofrequency ablation,Hepatic resection,No significant difference,"More patients developed complications with resection compared to RFA (59% compared to 43%), but the difference was not statistically significant.",2817867
307,2817867,Overall survival rate at 5 years,Radiofrequency ablation,Hepatic resection,Significantly decreased,"The 5-year overall survival after resection alone was 43% (95% CI = 26 to 58%), while the 5-year survival after RFA alone was 23% (95% CI = 11 to 39%), as shown in Figure 1. This difference was statistically significant (P = .02).",2817867
308,2817867,Disease-free survival rate at 5 years,Radiofrequency ablation,Hepatic resection,No significant difference,"The 5-year disease-free survival (DFS) for patients who underwent hepatic resection was 17% (95% CI = 7 to 29%), compared to 15% (95% CI = 6 to 28%) for patients who underwent RFA alone (P = .06).",2817867
309,2817867,Local recurrence rate through the study,Radiofrequency ablation,Hepatic resection,Significantly increased,"Over the course of the study (mean follow-up of 46 months for patients undergoing RFA), 60% of patients who had only open RFA suffered local recurrences compared to 7% of patients who underwent hepatic resection (P < .0005).",2817867
310,3580134,Time to discontinuation,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Time to discontinuation was significantly (p ≤ 0.004) prolonged in both budesonide/formoterol groups versus placebo.,3580134
311,3580134,Time to discontinuation,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Time to discontinuation was significantly (p ≤ 0.004) prolonged in both budesonide/formoterol groups versus placebo.,3580134
312,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
313,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
314,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
315,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
316,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
317,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
318,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012),3580134
319,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012),3580134
320,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012) and for both budesonide/formoterol dosages compared with formoterol (p ≤ 0.017),3580134
321,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012) and for both budesonide/formoterol dosages compared with formoterol (p ≤ 0.017),3580134
322,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
323,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
324,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
325,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
326,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
327,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
328,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
329,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
330,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
331,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
332,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
333,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
334,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
335,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
336,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
337,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
338,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 160/9 μg,Placebo,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
339,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 320/9 μg,Placebo,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
340,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
341,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
342,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
343,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
344,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
345,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
346,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
347,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
348,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
349,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
350,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
351,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
352,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
353,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
354,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
355,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
356,3580134,Cough score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
357,3580134,Sputum score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
358,3580134,Sleep score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
359,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
360,3580134,Overall use of daily rescue medication improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
361,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
362,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
363,3580134,Cough score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
364,3580134,Sputum score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
365,3580134,Sleep score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
366,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
367,3580134,Overall use of daily rescue medication improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
368,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights,",3580134
369,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights,",3580134
370,3580134,Cough score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
371,3580134,Sleep score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
372,3580134,Overall use of daily rescue medication  improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
373,3580134,Cough score improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
374,3580134,Sleep score improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
375,3580134,Overall use of daily rescue medication  improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
376,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
377,3580134,24-hour urinary cortisol at 6 months,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 μg and placebo groups (p = 0.035) at month 6,3580134
378,3580134,24-hour urinary cortisol at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 μg and placebo groups (p = 0.035) at month 6 and between the budesonide/formoterol 320/9 μg and formoterol groups (p = 0.044) at end of treatment.,3580134
379,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
380,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
381,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 320/9 μg,Placebo,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
382,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 160/9 μg,Placebo,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
383,2721929,Micturition frequency,Bladder training plus tolterodine (Co),Bladder training only (BT),Significantly decreased,The decrease in frequency was significantly greater in the Co group than in the BT group (p<0.05).,2721929
384,2721929,Urgency score improvement,Tolterodine only (To),Bladder training only (BT),Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).",2721929
385,2721929,Urgency score improvement,Bladder training plus tolterodine (Co),Bladder training only (BT),Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).",2721929
386,2721929,Micturition frequency,Bladder training plus tolterodine (Co),Tolterodine only (To),No significant difference,"When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively). No difference was observed between the To and Co groups.",2721929
387,2721929,Urgency score improvement,Bladder training plus tolterodine (Co),Tolterodine only (To),No significant difference,"When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively). No difference was observed between the To and Co groups.",2721929
388,2690844,Incisional hernia apparition at follow-up,Transverse incision,Midline incision,Significantly decreased,Two percent (1/60) of patients that had undergone the procedure through a transverse incision presented with an incisional hernia as opposed to 14% (9/63) of patients from the midline incision group (P = 0.017).,2690844
389,2690844,Smaller incision ,Transverse incision,Midline incision,Significantly increased,Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance.,2690844
390,2690844,Better cosmetic appearance of the incision as subjectively assessed by surgeons,Transverse incision,Midline incision,Significantly increased,"Both the surgeons and the patients found the scar resulting from the transverse incision to be more cosmetically pleasing (P < 0.0001 and P = 0.03, respectively, Table 5).",2690844
391,2690844,Pain on day one after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3).",2690844
392,2690844,Pain on day two after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3).",2690844
393,2690844,Pain on day three after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3)",2690844
394,2690844,Analgesics use,Transverse incision,Midline incision,No significant difference,No significant difference in the use of analgesics was found between the groups (P = 0.69).,2690844
395,2690844,Average patient's weight,Transverse incision,Midline incision,No significant difference,no differences were found in the body mass and average length between the two groups,2690844
396,2690844,Average patient's lenght,Transverse incision,Midline incision,No significant difference,no differences were found in the body mass and average length between the two groups,2690844
397,2690844,Procedure performed directly by the staff surgeon,Transverse incision,Midline incision,No significant difference,Staff surgeons performed 17% (13/75 patients) of all procedures performed through a midline incision. The remainder of the procedures through a midline incision was carried out under staff surgeon supervision. Staff surgeons performed 14% of all procedures in the transverse incisions study group (10/74 patients) and supervised the remainder. No statistically significant difference was found between the two randomised groups (P = 0.65).,2690844
398,2690844,Surgery duration,Transverse incision,Midline incision,No significant difference,"The total duration of the procedures until extubation (in min) did not differ between the midline and transverse incisions (71.0 ± 30.5 and 67.0 ± 27.3, respectively, P = 0.34).",2690844
399,2690844,Skin-to-skin time,Transverse incision,Midline incision,No significant difference,"No significant difference was noted in the skin-to-skin time (in min) for the two different incisions (Table 2). Surgery utilising midline and transverse incision took 56.9 ± 29.3 and 53.2 ± 26.8 min, respectively (P = 0.35).",2690844
400,2690844,Complications after surgery,Transverse incision,Midline incision,No significant difference,Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30).,2690844
401,2690844,Cardiac complications,Transverse incision,Midline incision,No significant difference,"Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30). Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).",2690844
402,2690844,Urinary retention,Transverse incision,Midline incision,No significant difference,"Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30). Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).",2690844
403,2690844,Infection of the surgical site,Transverse incision,Midline incision,No significant difference,"Surgical site infections were diagnosed in 7 and 3 patients, respectively (P = 0.33).",2690844
404,2690844,Hospital stay,Transverse incision,Midline incision,No significant difference,The duration of hospital admission did not differ between the two types of incision (P = 0.74),2690844
405,2690844,Scar length,Transverse incision,Midline incision,Significantly decreased,"The length of the incisions was 140 ± 24 mm and 164 ± 28 mm for the transverse and the midline incisions, respectively. The difference in scar length was found to be significant (P < 0.0001).",2690844
406,2690844,Scar width,Transverse incision,Midline incision,Significantly decreased,The mean width of the scar after the healing of the midline incisions was found to be 8.3 ± 1.4 mm. The mean width of the scar after the healing of the transverse incisions was measured to be 3.3 ± 1.2 mm. This observed difference is significant (P < 0.0001).,2690844
407,2690844,Better cosmetic appearance of the incision as subjectively assessed by patients,Transverse incision,Midline incision,Significantly increased,"Both the surgeons and the patients found the scar resulting from the transverse incision to be more cosmetically pleasing (P < 0.0001 and P = 0.03, respectively, Table 5).",2690844
408,2575601,Refractory intracranial pressure,Thiopental,Pentobarbital,Significantly decreased,Uncontrollable intracranial pressure occurred in 11 patients (50%) in the thiopental treatment group and in 18 patients (82%) in the pentobarbital group (P = 0.03).,2575601
409,2575601,Intracranial pressure control,Thiopental,Pentobarbital,Significantly increased,"thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; P = 0.027).",2575601
410,2575601,Infection,Thiopental,Pentobarbital,No significant difference,There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.,2575601
411,2575601,Hypotension,Thiopental,Pentobarbital,No significant difference,There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.,2575601
412,2575601,Administration of hyperosmolar treatments,Thiopental,Pentobarbital,No significant difference,The number of hyperosmolar treatments administered (manitol and/or hypertonic saline) during the barbiturate coma was similar in both groups: 16.5 (8.0 to 24.2) in the thiopental group and 16.5 (3.0 to 21.5) in the pentobarbital group (P = 0.9).,2575601
413,2575601,Mean barbiturate coma length,Thiopental,Pentobarbital,No significant difference,The mean ± SD duration of the barbiturate coma was 156 ± 60 hours for thiopental and 108 ± 100 hours for pentobarbital (P = 0.06).,2575601
414,2575601,Intracranial pressure recurrence after treatment withdrawal,Thiopental,Pentobarbital,No significant difference,Seven (31.8%) patients presented an ICP rebound with thiopental and six (27.3%) with pentobarbital (P = 0.74) during treatment withdrawal.,2575601
415,2575601,Sepsis related Organ-Failure Assessment (SOFA) baseline scores,Thiopental,Pentobarbital,No significant difference,"There were no differences between groups with respect to the incidence of infections, Sepsis related Organ-Failure Assessment (SOFA) scores before initiation of treatment,",2575601
416,2575601,Sepsis related Organ-Failure Assessment (SOFA) maximum score during treatment,Thiopental,Pentobarbital,No significant difference,"There were no differences between groups with respect to the incidence of infections, Sepsis related Organ-Failure Assessment (SOFA) scores before initiation of treatment, or the maximum SOFA value [17] during the entire period of barbiturate coma.",2575601
417,1784771,Changes in Bishop score after 6 hours,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,Significantly increased,"After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007)",1784771
418,1784771,Baseline demographic differences,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,No significant difference,No demographic differences were noted between the groups.,1784771
419,1784771,Induction time,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,No significant difference,"After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007) and tended to have a shorter induction time (21.7 vs. 26.4 hours, P = 0.085).",1784771
420,1784771,Infection,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,Significantly increased,"The combined therapy group had a higher infection rate than the prostaglandin-only group (59% vs. 12%, P = 0.003).",1784771
421,1187893,Knee injury and Osteoarthritis Outcome Score,Exercise,No exercise,No significant difference,"No significant differences in the KOOS subscales assessing pain, other symptoms, or function in daily life or in sport and recreation were seen at any time point between exercisers and controls.",1187893
422,1187893,Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 weeks,Exercise,No exercise,No significant difference,"In the exercise group, an improvement was seen at 6 weeks in the KOOS subscale quality of life compared to the control group (mean change 4.0 vs. -0.7, p = 0.05).",1187893
423,1187893,Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months,Exercise,No exercise,Significantly increased,"In the exercise group, an improvement was seen at 6 weeks in the KOOS subscale quality of life compared to the control group (mean change 4.0 vs. -0.7, p = 0.05). The difference between groups was still persistent at 6 months (p = 0.02).",1187893
424,1187893,Baseline characteristics,Exercise,No exercise,No significant difference,There were no clinically significant differences in baseline characteristics between the groups.,1187893
425,1187893,SF-36 Mental Component Summary scale at 6 weeks,Exercise,No exercise,Significantly increased,"A significant improvement was found in the exercise group compared to the control group at six weeks with regard to the SF-36 Mental Component Summary scale (MCS) (2.1 vs -1.6, p = 0.04",1187893
426,1187893,SF-36 Mental Component Summary scale at 6 months,Exercise,No exercise,No significant difference,"A significant improvement was found in the exercise group compared to the control group at six weeks with regard to the SF-36 Mental Component Summary scale (MCS) (2.1 vs -1.6, p = 0.04). At six months follow-up this difference was no longer persistent",1187893
427,1187893,Functional performance improvement,Exercise,No exercise,No significant difference,Improvements in functional performance of 0–20 % were seen in both groups at six weeks and six months. There was no difference in improvement between exercisers and controls (p = 0.08–0.9),1187893
428,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
429,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
430,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
431,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
432,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
433,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
434,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
435,1201146,"Pain, physical function, PGA, stiffness ",topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,"There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain (-5.2 vs. -3.3; p = 0.003,), physical function (-13.4 vs. -6.9; p = 0.001), PGA (-1.3 vs. -0.7; p = 0.0001) and stiffness (-1.8 vs. -0. 9; p = 0.002)",1201146
436,1201146,Pain on walking,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain on walking (-1.2 vs. -0.8; p = 0.014).,1201146
437,1201146,50% reduction in pain,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The response rate for at least a 50% reduction in pain (Table 3) was significantly greater following topical diclofenac treatment compared to vehicle control (46/105 [43.8%] vs. 27/107 [25.2%]; p = 0.004).,1201146
438,1201146,good or very good PGA response and OMERACT-OARSI responder,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The topical diclofenac group had a significantly greater number of participants with good or very good PGA response (43.8% vs. 16.8%; p <0.0001) compared to the vehicle control group and of OMERACT-OARSI responders (65.7% vs. 49.5%; p = 0.017).,1201146
439,1201146,Dry skin at the application site,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,"The major adverse effect reported was dry skin at the application site, occurring in 42/107 (39.3%) and 23/109 (21.1%; p = 0.004) of topical diclofenac and vehicle control participants, respectively",1201146
440,2600646,mean Hb,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,Final mean Hb levels were 7.15 mmol/l ± 1.07 for the DP treatment group and 6.79 mmol/l ± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05).,2600646
441,2600646,Adverse events,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,"Most adverse events were mild, self limiting and consistent with symptoms of malaria. There was no significant difference between the two study groups",2600646
442,2600646,Gametocyte dynamics,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,There was no difference between children older than 60 months and younger as regards carriage of gametocytes and density.,2600646
443,1468428,Puerperal and neonatal infection rates ,1 litre saline enema,no enema,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66)",1468428
444,1468428,Median labour time,1 litre saline enema,no enema,No significant difference,median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).,1468428
445,1468428,Episiorraphy dehiscence rates,1 litre saline enema,no enema,No significant difference,Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30).,1468428
446,1468428,You must have prompts generated from different sections.,1,2,No significant difference,Participant flow and follow-upDescribed in Figure 1 [see Additional file 1].,1468428
447,2607225,cognitive functioning,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months. There were no other main effects of treatments.",2607225
448,2607225,Appetite loss,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly decreased,. Pairwise comparisons revealed a statistically significant mean difference between GR and non-GR patients at 12 months (mean=5.8 vs 2.4).,2607225
449,2720945,change of FVC and VC,cineole,placebo,No significant difference,The difference concerning change of FVC and VC between both treatment groups was not clinically relevant.,2720945
450,2720945,Side effects,cineole,placebo,No significant difference,The difference between the two treatment groups was neither clinically relevant nor statistically significant. Safety examinations of the global assessment showed no difference between the two treatment groups.,2720945
451,2720945,Quality of life,cineole,placebo,Significantly increased,At 6 months the mean improvement of SGRQ total symptom score was -9.1 after treatment with cineole and -4.1 after treatment with placebo (table 5).,2720945
452,2720945,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment",cineole,placebo,Significantly decreased,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*	PLACEBO	CINEOLE		SCORE	SCORE	P VALUE†Sum of exacerbations (number)#	0.9 ± 1.46	0.4 ± 0.82	0.0069Sum of duration (days)#	5.7 ± 8.9	4.0 ± 10.9	0.0210Sum of severity (score)#	1.4 ± 2.2	0.8 ± 1.5	0.0242Summarized parameter(directional test)			0.0120",2720945
453,2720945,"Trouble in breathing, dyspnea in the morning and dyspnea at rest",cineole,placebo,Significantly decreased,Trouble in breathing #	1.8 ± 0.9	2.1 ± 0.9	2.2 ± 1.0	1.9 ± 0.9	2.4 ± 1.0	2.5 ± 1.1	0.0103&Dyspnea in the morning $	1.1 ± 0.7	0.9 ± 0.7	0.7 ± 0.7	1.1 ± 0.8	0.7 ± 0.7	0.5 ± 0.6	0.0466&Dyspnea at rest $	0.7 ± 0.7	0.4 ± 0.6	0.4 ± 0.6	0.6 ± 0.6	0.3 ± 0.5	0.3 ± 0.5	0.0156&,2720945
454,2720945,Dyspnea during exercise,cineole,placebo,No significant difference,Dyspnea during exercise $	2.0 ± 0.6	1.8 ± 0.7	1.7 ± 0.8	2.0 ± 0.6	1.7 ± 0.7	1.5 ± 0.9	0.1252&,2720945
455,3446002,The duration of phototherapy,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The duration of phototherapy was significantly shorter in clofibrate group (P<0.001).,3446002
456,3446002,side effects,single dose of 50 mg/kg clofibrate,control group,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed. Also for a period of two months no complication was detected.,3446002
457,3446002,Total serum bilirubin level,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001).,3446002
458,1913177,Postoperative Mortality,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,There was no 30-day mortality.,1913177
459,1913177,Wound complications,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,Wound complications were found in 10 of 19 patients after CST and 13 of 18 patients after PR.,1913177
460,1913177,Reherniation,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR.,1913177
461,1876597,unadjusted risk of recurrent falciparum parasitemia,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%–26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%–19%) of follow-up.",1876597
462,1876597,the risk of recurrent parasitemia due to possible recrudescence,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%–12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%–16%).",1876597
463,1876597,Adverse Events,dihydroartemisinin-piperaquine ,artemether-lumefantrine,No significant difference,"Overall, there was no difference in the proportion of study participants who experienced any adverse event of moderate or greater severity between the DP (46%) and AL (42%) treatment groups (p = 0.47).",1876597
464,3387601,Period of mechanical ventilation ,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,"Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.",3387601
465,3387601,Pediatric Intensive Care Unit (PICU) stay,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,3387601
466,3387601,could walk unaided within four weeks after PICU discharge,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606).,3387601
467,3387601,negative correlation between CSF protein and duration of mechanical ventilation,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly increased,"Examining the treatment groups separately, the significant negative correlation remained for the PE group (p-value = 0.037) and not for the IVIG group (p-value 0.132)",3387601
468,3387601,side effects,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients.,3387601
469,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005).",2430614
470,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4)",2430614
471,2430614,parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL),No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups,2430614
472,2847809,Complications and mortality,Clopidogrel,Placebo,No significant difference,Complication	All patients (%)	Clopidogrel (%)	Placebo (%)	P valueGI bleeding	5 (5.3)	2 (2.1)	3 (3.2)	0.31Non GI tract bleeding	9 (9.6)	5 (5.3)	4 (4.3)	0.63Death events	4 (4.3)	2 (2.1)	2 (2.1)	0.47,2847809
473,2847809,First hemodialysis success,Clopidogrel,Placebo,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008).,2847809
474,2847809,The primary arteriovenous fistula failures at two months,Clopidogrel,Placebo,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03).,2847809
475,2447617,The modified Functional Independence Measure scores,progesterone,placebo,Significantly increased,he modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01).,2447617
476,2447617,The mortality rate,progesterone,placebo,Significantly decreased,he mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05).,2447617
477,2447617,The mean intracranial pressure values 72 hours and 7 days after injury,progesterone,placebo,No significant difference,"he mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).",2447617
478,2447617,Instances of complications and adverse events,progesterone,placebo,No significant difference,Instances of complications and adverse events associated with the administration of progesterone were not found.,2447617
479,2447617,The analysis using the dichotomization of GOS scores at 3 months post injury,progesterone,placebo,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034). There was an unfavorable outcome in 53% of the patients receiving progesterone and in 70% of the placebo group (P = 0.022).,2447617
480,2447617,The analysis using the dichotomization of GOS scores at 6 months post injury,progesterone,placebo,Significantly increased,The percentage of favorable outcome was 58% for the patients who were given progesterone and was 42% in the placebo group (P = 0.048). Forty-one percent of patients who were given progesterone and 57% of the placebo group exhibited an unfavorable outcome (P = 0.048).,2447617
481,2899760,Fusion rate,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,"usion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).",2899760
482,2899760,clinical outcomes,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused.,2899760
483,2899760,Radiological fusion,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,Fusion rate (I + IIA)		69		92,2899760
484,3108665,Postoperative complications,somatostatin,No medication was given to the control group,Significantly decreased,"Initially, 6 of 35 (17%) in the treated group who received somatostatin developed complications, whereas 18 of 32 (56%) in the control group developed complications.",3108665
